Literature DB >> 11796990

One step forwards, one step back.

Jeffrey D Lifson, Malcolm A Martin.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 11796990     DOI： 10.1038/415272b

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  13 in total

1.  Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.

Authors:  Philip R Johnson; Bruce C Schnepp; Mary J Connell; Daniela Rohne; Suzanne Robinson; Georgia R Krivulka; Carol I Lord; Rebekah Zinn; David C Montefiori; Norman L Letvin; K Reed Clark
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Importance of B-cell responses for immunological control of variant strains of simian immunodeficiency virus.

Authors:  Welkin E Johnson; Jeffrey D Lifson; Sabine M Lang; R Paul Johnson; Ronald C Desrosiers
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.

Authors:  Kenji Someya; Dayaraj Cecilia; Yasushi Ami; Tadashi Nakasone; Kazuhiro Matsuo; Sherri Burda; Hiroshi Yamamoto; Naoto Yoshino; Masahiko Kaizu; Shuji Ando; Kenji Okuda; Susan Zolla-Pazner; Shudo Yamazaki; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

4.  CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.

Authors:  Koen K A Van Rompay; Raman P Singh; Bapi Pahar; Donald L Sodora; Casey Wingfield; Jonathan R Lawson; Marta L Marthas; Norbert Bischofberger
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

5.  Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge.

Authors:  Nancy A Wilson; Brandon F Keele; Jason S Reed; Shari M Piaskowski; Caitlin E MacNair; Andrew J Bett; Xiaoping Liang; Fubao Wang; Elizabeth Thoryk; Gwendolyn J Heidecker; Michael P Citron; Lingyi Huang; Jing Lin; Salvatore Vitelli; Chanook D Ahn; Masahiko Kaizu; Nicholas J Maness; Matthew R Reynolds; Thomas C Friedrich; John T Loffredo; Eva G Rakasz; Stephen Erickson; David B Allison; Michael Piatak; Jeffrey D Lifson; John W Shiver; Danilo R Casimiro; George M Shaw; Beatrice H Hahn; David I Watkins
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

6.  Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans.

Authors:  David I Watkins; Dennis R Burton; Esper G Kallas; John P Moore; Wayne C Koff
Journal:  Nat Med       Date:  2008-06       Impact factor: 53.440

7.  From HIV infection to AIDS: a dynamically induced percolation transition?

Authors:  Christel Kamp; Stefan Bornholdt
Journal:  Proc Biol Sci       Date:  2002-10-07       Impact factor: 5.349

8.  A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge.

Authors:  Matthew R Reynolds; Andrea M Weiler; Shari M Piaskowski; Michael Piatak; Henry T Robertson; David B Allison; Andrew J Bett; Danilo R Casimiro; John W Shiver; Nancy A Wilson; Jeffrey D Lifson; Wayne C Koff; David I Watkins
Journal:  Vaccine       Date:  2012-05-06       Impact factor: 3.641

9.  Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239.

Authors:  Bin Jia; Sharon K Ng; M Quinn DeGottardi; Michael Piatak; Eloísa Yuste; Angela Carville; Keith G Mansfield; Wenjun Li; Barbra A Richardson; Jeffrey D Lifson; David T Evans
Journal:  PLoS Pathog       Date:  2009-01-23       Impact factor: 6.823

10.  Protection against high-dose highly pathogenic mucosal SIV challenge at very low serum neutralizing titers of the antibody-like molecule CD4-IgG2.

Authors:  Pascal Poignard; Brian Moldt; Karla Maloveste; Noëlie Campos; William C Olson; Eva Rakasz; David I Watkins; Dennis R Burton
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.